PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial.

Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: subgroup analysis from KATHERINE

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Impact of Pembrolizumab Versus Chemotherapy on Health-Related Quality of Life in Patients with Metastatic Triple Negative Breast Cancer

Final results of the double-blind placebo (PBO)-controlled randomised phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase 3 BROCADE3 trial

Tucatinib vs Placebo Added to Trastuzumab and Capecitabine in Previously Treated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB)

PREDIX HER2 trial: event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels

CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses

Circulating tumor cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)

BioItaLEE – Comparative Biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

Quality of life (QoL) with Palbociclib (PAL) plus endocrine therapy (ET) versus (vs) Capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)

Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumors

A window-of-opportunity Study with atezolizumab and the oncolityc virus pelareorep in early Breast Cancer (REO-027, AWARE-1)